Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDN1 Mutation Is Associated With High Tumor Mutation Burden and Unfavorable Prognosis in Breast Cancer

21 Mar 2022

Abstract excerpt

Background: Breast cancer (BRCA) is the most common cancer worldwide and a serious threat to human health. MDN1 mutations have been observed in several cancers. However, the associations of MDN1 mutation with tumor mutation burden (TMB) and prognosis of BRCA have not been investigated. Methods: Genomic, transcriptomic, and clinical data of 973 patients with BRCA from The Cancer Genome Atlas (TCGA) database were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Cancer Genomics and Diagnostics
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35386280
DOI: 10.3389/fgene.2022.857836

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDN1 Mutation Is Associated With High Tumor Mutation Burden and Unfavorable Prognosis in Breast CancerPMID 35386280Read ↗

The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.Semantic proximity Read ↗

ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.Semantic proximity Read ↗

The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers.Semantic proximity Read ↗

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigmsSemantic proximity Read ↗

CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancerSemantic proximity Read ↗

Identification and validation of molecular subtypes and a 9-gene risk model for breast cancer.Semantic proximity Read ↗

Circulating Tumor DNA Mutation Profiling Reveals Prognostic Signatures in Breast CancerSemantic proximity Read ↗

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic VulnerabilitiesSemantic proximity Read ↗

BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far.Semantic proximity Read ↗

Characterizing neurofibromin 1-altered breast cancer through genomic, functional, and clinical analyses.Semantic proximity Read ↗

Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insightsSemantic proximity Read ↗

PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.